周二，礼来(LLY.US)股价盘前走低，截至发稿，该股跌超1.5%，报1042.5美元。消息面上，礼来主要竞 争对手诺和诺德(NVO.US)宣布，将下调旗下多款GLP-1类药物在美国的官方标价。 诺和诺德表示，自2027年1月1日起，公司将下调Wegovy、Ozempic和Rybelsus在美国市场的批发采购 价。调整后，Wegovy和Ozempic的标价将较当前水平下调约35%至50%，相关调整同时适用于注射剂型 和口服剂型。 具体来看，此次定价改革将把Wegovy注射剂和口服版本，以及Ozempic注射剂和Rybelsus口服药的月度 标价统一降至675美元。目前，在利润丰厚的抗肥胖药物市场中，诺和诺德的市场表现仍落后于礼来。 公司还指出，价格下调预计将尤其利好自付费用与官方标价挂钩的患者。不过，诺和诺德强调，此次调 整不会影响其直面消费者的自费定价体系。 诺和诺德在声明中表示，此次降价适用于上述药物的所有剂量，体现了公司在美国医疗体系不断演变的 背景下，提升患者以及公共和私人支付方用药可负担性的承诺。 ...

（原标题：美股异动 | 礼来(LLY.US)盘前跌超1.5% 竞争对手诺和诺德(NVO.US)宣布下调GLP-1药物标 价） 智通财经APP获悉，周二，礼来(LLY.US)股价盘前走低，截至发稿，该股跌超1.5%，报1042.5美元。消 息面上，礼来主要竞争对手诺和诺德(NVO.US)宣布，将下调旗下多款GLP-1类药物在美国的官方标 价。 具体来看，此次定价改革将把Wegovy注射剂和口服版本，以及Ozempic注射剂和Rybelsus口服药的月度 标价统一降至675美元。目前，在利润丰厚的抗肥胖药物市场中，诺和诺德的市场表现仍落后于礼来。 诺和诺德在声明中表示，此次降价适用于上述药物的所有剂量，体现了公司在美国医疗体系不断演变的 背景下，提升患者以及公共和私人支付方用药可负担性的承诺。 公司还指出，价格下调预计将尤其利好自付费用与官方标价挂钩的患者。不过，诺和诺德强调，此次调 整不会影响其直面消费者的自费定价体系。 诺和诺德表示，自2027年1月1日起，公司将下调Wegovy、Ozempic和Rybelsus在美国市场的批发采购 价。调整后，Wegovy和Ozempic的标价将较当前水平下调约35%至50 ...

Group 1 - The core viewpoint of the articles highlights the continued high demand for Chinese innovative drugs in global markets, with significant business development (BD) transactions occurring in early 2026, indicating a strong growth trajectory for the industry [1][2]. - As of February 15, 2026, there have been 39 license-out transactions for Chinese innovative drugs, with an upfront payment of approximately $2.953 billion and a total value exceeding $49 billion, surpassing one-third of the total amount for 2025 [1]. - Morgan Stanley's report emphasizes a positive long-term outlook for the Chinese pharmaceutical industry, identifying "catalysts" as a key theme, with expectations for numerous catalysts in 2026 that will enhance the global value of domestic pharmaceutical assets [2]. Group 2 - Morgan Stanley specifically mentions that 2025 saw a total BD transaction amount of $135.7 billion for Chinese innovative drugs, surpassing the U.S. for the first time, with 2026 showing even stronger growth as the first 49 days of transactions exceeded any single quarter in 2025 [2]. - The report highlights Hengrui Medicine as a preferred investment target, predicting accelerated sales growth in 2026 and a positive trend in new cooperative transactions, which are crucial for realizing milestone payments [2]. - The transformation of Kangzhe Pharmaceutical towards innovative drugs is noted, with the approval of a targeted drug for vitiligo, indicating a significant step in the company's transition and growth strategy [3]. Group 3 - Despite the ongoing BD transaction boom, the innovative drug sector is experiencing a market downturn, with the Hong Kong innovative drug ETF dropping 0.78% after the Spring Festival, indicating a disconnect between market sentiment and fundamentals [4]. - The focus of BD transactions in 2026 is shifting towards early-stage research projects, with over 50% of the 39 transactions being in preclinical stages, reflecting a strategic pivot in the industry [5]. - Companies like Kangfang Biotech are optimistic about the global impact of Chinese innovative drugs, aiming to expand their global footprint and enhance their international presence in drug development [5].

作为中国医药工业体系中的"隐形巨擘"，某总部位于华东的医药集团（以下简称"该集团"或"集团"）长 期占据中国医药工业百强榜首位置，其发展历程是中国本土药企从"仿制药规模化"向"创新药差异化"转 型的经典缩影。 本报告对该集团进行了全方位的解构，核心发现包括： 1. 集团概况与历史沿革：从地方小厂到行业巨头 1.1 创始背景与早期积累（1971-2000） 该集团的历史可以追溯到1971年。创始人在江苏省泰州市的一个口岸镇创办了集团的前身。创业初期， 企业主要以生产板蓝根、维生素等基础药物为主，不仅面临资金短缺，更受限于当时计划经济体制下的 统购统销模式。 在1980年代至1990年代，创始人敏锐地抓住了中国医疗卫生体制改革的机遇，确立了"质量兴企"的战略 基石。不同于当时许多乡镇企业追求短期利益的做法，该集团在早期就建立了严格的质量内控标准，这 为其后来在"板蓝根大战"等行业洗牌中脱颖而出奠定了基础。集团充分利用长三角（上海、苏州、杭 州）的地理优势，逐步建立了覆盖华东、辐射全国的销售网络。 1.2 爆发式增长与行业霸主地位（2000-2019） 进入21世纪，该集团迎来了黄金发展期。2003年至2010年间 ...

诺和诺德宣布大幅下调明星减肥药Wegovy及Ozempic在美国市场的标价，司美格鲁肽系列药物月度标价统一为675美元，降幅最高达50%，新定价 将于明年1月1日生效。此举标志着这家丹麦药企在肥胖症市场的竞争策略出现重大转向。 消息公布后，诺和诺德美股盘前下跌3%，礼来美股盘前一度跌逾4%。值得注意的是，诺和诺德本周一刚公布下一代药物CagriSema又一组令人失 望的试验数据，此后股价已累计下跌约19%。降价决定在此背景下出炉，进一步加剧市场担忧。 此次降价是诺和诺德在肥胖症市场竞争中失去领先地位后的主动应对。礼来竞品Zepbound目前标价为每月1086.37美元，诺和诺德统一定价至675 美元后，在标价层面形成明显价格优势。 诺和诺德美国业务负责人Jamey Millar表示，此次降价不会对公司净销售额产生直接影响，但对获得支付方认可持乐观态度。Millar曾任职于 UnitedHealth Group旗下药品福利管理机构Optum Rx，深谙美国药品定价策略。他表示： "支付方此前已公开呼吁降低药品标价，我有信心他们将接受并欢迎这些更低的标价。" 高免赔额计划患者受益最大 此次降价针对的是批发采购成本 ...

这家丹麦药企将司美格鲁肽全系列药物月均统一定价为675美元，降幅高达50%。其美国竞争对手礼来 (LLY.US)的同类减肥药物Zepbound，目前官方定价为1086.37美元/月。 智通财经APP获悉，诺和诺德(NVO.US)计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美 国官方定价，以在肥胖症治疗市场争夺更大份额。 目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。Millar曾任职于联合健康 (UNH.US)旗下药品福利管理机构Optum Rx，是美国定价策略方面的专家。 新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变 化。 他指出，此次调整对高免赔额保险人群影响尤为明显——这类保单的自付费用与官方定价高度挂钩;按 药品定价比例付费的共付保险患者，同样将受益。 据KFF的雇主健康福利调查，去年约三分之一参保职工选择了高免赔额医保搭配个人健康储蓄账户方 案;调查同时显示，不到一半的大型企业为Wegovy这类GLP-1减重药物提供医保报销。 此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。在商业保 ...

ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(以下简称"国家药监局") 核准签发的关于吸入用异丙托溴铵溶液《药品注册证书》。上述药品获得《药品注册证书》，将进一步 丰富公司产品线，对公司的发展起到积极作用。 ...

Investment Rating - The investment rating for the company is "Buy" [2][10] Core Insights - The company is a leading domestic specialized commercialization enterprise, and its innovative transformation has initiated a new growth cycle [5][18] - The company has excellent commercialization capabilities and a comprehensive research, production, and sales layout in the Southeast Asian market [6][20] - The company has four major business segments that are progressing in synergy, with stable contributions from cardiovascular and digestive health, and new growth momentum from skin health and ophthalmology [7][19] - The innovative pipeline is entering a harvest period, with multiple innovative products nearing commercialization [8][19] - The company has strong profitability and cash flow, providing a solid safety net for its innovative transformation and maintaining a stable high dividend policy [21] Summary by Sections 1. Company Overview - Founded in 1992, the company has evolved from a pharmaceutical agency to an innovative comprehensive pharmaceutical enterprise [22] - The company has a clear shareholding structure, with the actual controller being Mr. Lin Gang [28] - The negative impact of centralized procurement has been largely digested, with revenue and profit growth turning positive in the first half of 2025 [30] 2. Commercialization Capabilities - The company has a robust commercialization system, covering over 50,000 hospitals and 300,000 retail pharmacies, supported by a professional team of approximately 4,700 academic promoters [39] - The company has established a complete strategic layout in Southeast Asia, integrating research, registration, commercialization, and manufacturing [47] 3. Business Segments - The cardiovascular segment contributes approximately 48% of revenue, with the impact of centralized procurement clearing up and new products gaining traction [54] - The digestive and autoimmune segment accounts for about 30% of revenue, with stable growth from exclusive products and significant potential from innovative products [7] - The skin health segment, operated independently by a subsidiary, has high growth potential, with plans for a separate listing to reassess its value [7] - The ophthalmology segment contributes around 8% of revenue, with a competitive product portfolio including exclusive products and newly introduced drugs [7] 4. Innovative Pipeline - The company has nearly 40 innovative products in its pipeline, with six already commercialized and several others nearing NDA submission [8][19] - Key innovative products include Y-3 for acute ischemic stroke, Dexamethasone for chronic kidney disease, and ZUNVEYL for Alzheimer's disease, with peak sales potential exceeding 10 billion [8][19] 5. Financial Forecasts - Revenue projections for 2025-2027 are estimated at 82.16 billion, 98.59 billion, and 120.28 billion respectively, with year-on-year growth rates of 10%, 20%, and 22% [9] - Net profit forecasts for the same period are 16.15 billion, 18.50 billion, and 22.38 billion, with growth rates of 0%, 15%, and 21% [9]

益佰制药（600594.SH）2月24日在投资者互动平台表示，您好，我司建立财务管理中心，并未建立财 务共享中心。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好！ 1、请问贵公司是否已经建立财务 共享中心？哪年建立的？ 2、财务共享中心在技术上采用了哪些自动化或智能化工具？数字化程度按照 0-10打分得几分？ 3、财务共享中心的数量有几个？这些中心的设立是基于地理区域划分，还是按业务 板块划分？ ...

针对业绩变动的原因，艾迪药业表示，报告期内因抗HIV创新药收入的增加、合并南大药业的经营数据 等原因，导致主营业务毛利较上年同期增加了约25500万元；报告期内因公司加大新药推广力度、合并 南大药业的经营数据等原因，本期销售费用支出较上年同期增加了约9200万元；报告期内公司因市场开 拓与预期变化趋于平稳，本期的资产减值损失较上年同期减少了约4800万元。 北京商报讯（记者 丁宁）2月24日晚间，艾迪药业（688488）发布2025年度业绩快报显示，报告期内， 公司实现营业收入7.21亿元，同比增长72.49%；归属净利润-1973.37万元，同比实现减亏。 ...